{"id":"W2926019209","doi":"10.1093/rheumatology/kez063.086","title":"362. COMPARISON OF EFFICACY AND SAFETY BETWEEN TOCILIZUMAB AND CYCLOPHOSPHAMIDE IN TREATING PATIENTS WITH TAKAYASU’S ARTERITIS","year":2019,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Vasculitis and related conditions","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Medical Research Council; National Institutes of Health; Ministry of Health, Labour and Welfare; Canadian Institutes of Health Research; National Institute for Health and Care Research; Fresenius Medical Care North America; National Health and Medical Research Council; Japan Agency for Medical Research and Development","keywords":"Medicine; Tocilizumab; Cyclophosphamide; Takayasu arteritis; Takayasu's arteritis; Dermatology; Vasculitis; Arteritis; Internal medicine; Chemotherapy; Rheumatoid arthritis; Disease","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000684611,0.0001469418,0.0005274442,0.0002924722,0.0001664927,0.0002213552,0.00011753,0.0002892899,0.000806228],"category_scores_gemma":[0.001352382,0.00009460955,0.0004398867,0.0002737243,0.0001800785,0.0001685142,0.0001019972,0.0002687269,0.0001631494],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002431737,"about_ca_system_score_gemma":0.0001946121,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002991653,"about_ca_topic_score_gemma":0.0003353258,"domain_scores_codex":[0.9995989,0.0001482936,0.00007330146,0.00005937096,0.0000806047,0.00003956754],"domain_scores_gemma":[0.9991695,0.0003005154,0.0002935358,0.00004098752,0.00007060847,0.0001249282],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1527686,0.002687763,0.6902126,0.0008166371,0.001423413,0.0009026034,0.0002618411,0.0007754301,0.01302898,0.0001152566,0.0005925273,0.1364144],"study_design_scores_gemma":[0.007497131,0.07905542,0.903339,0.00006485268,0.00115492,0.002340667,0.0001220791,0.001073844,0.003256402,0.00008221449,0.001986432,0.00002699103],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9973797,0.002042586,0.00005758896,0.0000226166,0.00001316987,0.00002377521,0.00007588025,0.000003520327,0.0003811701],"genre_scores_gemma":[0.9992931,0.0002978144,0.00009046526,0.00003161654,0.00003276197,0.00002315002,0.000167779,6.783766e-7,0.00006269789],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.000806228,"threshold_uncertainty_score":0.003620565,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008052275048843285,"score_gpt":0.2458564401005441,"score_spread":0.2378041650517008,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}